Clotawin-T

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clotawin-T

Quick Facts

Property Description
Active ingredients Tranexamic Acid, Ethamsylate
Form Tablet (Oral preparation)
Pharmacological class Antifibrinolytic Agent (Tranexamic Acid), Hemostatic Agent (Ethamsylate)
Common use Systemic control of excessive bleeding
Origin Synthetic compound

What is Clotawin-T and its Pharmacological Class?

Clotawin-T is a prescription medicine classified as a combination hemostatic agent, a type of drug used to help the body manage and control hemorrhage. Its most recognized anti-bleeding action is driven by Tranexamic Acid, which is classified as a systemic Antifibrinolytic Agent. An antifibrinolytic agent is utilized to prevent the premature breakdown of existing blood clots, thereby helping the body control or reduce excessive blood loss. Tranexamic Acid has a fundamental role in patient blood management and is recognized as critical for managing various types of hemorrhage.

Composition, Origin, and Pharmaceutical Type

The Clotawin-T formulation is distinguished by its dual composition, containing two primary active ingredients: Tranexamic Acid and Ethamsylate. Tranexamic Acid is a synthetic compound derived from the amino acid lysine, offering direct action against clot dissolution. The accompanying component, Ethamsylate, provides hemostatic support through a separate pathway, primarily by stabilizing capillary walls and enhancing the adhesion of platelets. The combined effect of these two components offers a multi-pathway approach to controlling bleeding. Clotawin-T is supplied as an oral preparation in the solid tablet dosage form, which ensures the predictable systemic delivery of both synthetic active substances to support the overall hemostatic balance, differentiating it from single-ingredient formulations.

Regulatory References

  1. WHO Essential Medicines List
  2. Tranexamic acid on WHO EML

What side effects are possible with Clotawin-T ?

Possible Side Effects and Safety Information

The safety profile for Clotawin-T, a combination of Tranexamic Acid and Ethamsylate, is characterized by adverse reactions grouped according to frequency and affected body systems, as documented in official regulatory sources (FDA, SmPC).

Common Adverse Reactions

Adverse reactions classified as Common (occurring in ge 1/100 people) primarily affect the Gastrointestinal System and general well-being. These include nausea, vomiting, diarrhea, abdominal discomfort, and headache. Regulatory documents note that gastrointestinal effects may sometimes resolve or lessen if a dosage reduction is implemented.

Serious Safety Concerns and Restrictions

The most significant safety constraint involves the documented risk of Thromboembolic Events (blood clots), which are classified as Rare to Very Rare but serious. This includes the possibility of venous or arterial thrombosis, such as deep vein thrombosis or pulmonary embolism. The medicine is officially Contraindicated (should not be used) in patients with a history of or active arterial or venous thrombosis, active intravascular clotting, a history of convulsions, and severe renal impairment.

Other serious, yet rare, documented reactions include convulsions (seizures), severe allergic reactions (anaphylaxis), and significant visual disturbances (e.g., impaired colour vision). If visual disturbances occur, the official labeling requires the medicine to be discontinued and an ophthalmological evaluation performed.

Population-Specific Safety Notes

Severe renal impairment is a constraint due to the risk of active substance accumulation. Older adults may be more susceptible to adverse reactions. Furthermore, the active substance passes into breast milk, and breast-feeding is generally not recommended while taking this medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Clotawin-T (which contains the antifibrinolytic agent tranexamic acid) is a serious medical event. It is essential to seek immediate medical assistance if an overdose is suspected, regardless of whether symptoms are present.

Regulatory documentation outlines that an overdose may affect the central nervous system, cardiovascular, and gastrointestinal systems. Documented overdose presentations include nausea, vomiting, and diarrhea. More severe effects involve the central nervous system, such as headache, dizziness, and the potential for convulsions (seizures). Low blood pressure (hypotension) has also been reported, particularly if the main component is administered too rapidly via injection.

Immediate emergency medical treatment is required if the following serious signs occur:

  • Convulsions or Seizures: Any uncontrolled physical shaking or loss of consciousness.
  • Vision Changes: Loss of vision, blurred vision, or any other changes in eyesight.
  • Signs of a Clot: Pain, swelling, warmth, or redness in the leg, or sudden shortness of breath and chest pain.
  • Collapse or Difficulty Breathing: The person has collapsed, cannot be awakened, or has trouble breathing.

In these severe cases, or if an overdose is suspected, contact emergency medical services immediately. The promptness of emergency care is critical for managing potential severe toxicity, particularly the risk of seizures.

Therapeutic Uses of Clotawin-T

What Clotawin-T Treats: Main Uses and Benefits

Clotawin-T is a combination of two agents, Tranexamic Acid and Ethamsylate, commonly used to provide systemic support for controlling excessive bleeding. The therapeutic approach is applied across domains where additional symptomatic assistance is needed to manage blood loss, aligning with established therapeutic indications.

Managing Heavy and Prolonged Menstrual Bleeding

The medication is applied across domains where additional symptomatic support is needed, and is commonly used to help manage symptoms associated with conditions such as heavy and prolonged menstrual flow (Menorrhagia). The therapeutic role is to support the body's processes to help manage symptomatic blood volume and duration, which assists with easing the overall symptom burden and supports improved comfort during these recurrent episodes.

Controlling Blood Loss in Acute Clinical Contexts

Clotawin-T is relevant for supportive symptom management of excessive blood loss following surgical or dental procedures, or for support in acute hemorrhagic episodes from various sources. It is applied in situations requiring short-term hemostatic assistance to support the patient during this phase and contribute to easing the total blood loss during periods of heightened physiological strain.


Quick Fact: Supportive Management for Excessive Blood Flow

Symptom Domain General Benefit
Abnormal Uterine Bleeding Helps manage symptomatic blood volume and duration.
Procedural Hemorrhage Supports symptom relief in surgical contexts.
Acute Bleeding May assist in the management of episodes of significant blood loss.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus

Eligibility and Restrictions for Use

Who Can and Cannot Use Clotawin-T?

The eligibility for Clotawin-T is strictly defined by regulatory authorities and is based on a patient's underlying health conditions and physiological state. The medicine is primarily intended for adult patients requiring systemic support for controlling excessive bleeding.


Contraindications: Who Must Not Use Clotawin-T

Use is contraindicated (absolutely prohibited) in individuals with specific conditions, primarily due to the active antifibrinolytic component:

  • Active or History of Thromboembolic Disease: This includes individuals with diagnosed Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or retinal vascular occlusion.
  • Severe Renal Impairment: The drug must not be used in patients with severe kidney problems, due to the risk of accumulation.
  • Specific Comorbidities: Contraindicated in patients with a history of convulsions or the metabolic disorder Porphyria.
  • Hypersensitivity: Known hypersensitivity to either Tranexamic Acid or Ethamsylate.

Population Restrictions and Conditional Use

Population Group Regulatory Status Condition for Use
Mild to Moderate Renal Impairment Conditional Use Requires mandatory dosage reduction and adjustment.
Pregnancy (First Trimester) Not Recommended Use is not recommended due to insufficient safety data.
Lactation/Breastfeeding Not Recommended Use is not recommended, as the active substance is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clotawin-T is a combination medicine containing Tranexamic Acid, an antifibrinolytic agent, and Ethamsylate. The officially documented interaction profile is largely governed by the thromboembolic risk associated with Tranexamic Acid’s activity.


Formally Contraindicated Combination

Co-administration with Combined Hormonal Contraceptives is strictly contraindicated. Regulatory labeling states this prohibition is due to the potential for a pharmacodynamic synergism that may further increase the established risk of venous and arterial thromboembolic events.


Documented Pharmacodynamic Interactions

Interacting Product Category Official Interaction Outcome
Prothrombotic Medical Products (e.g., Factor IX Complex Concentrates) Use must be avoided due to an increased risk of thromboembolic adverse reactions.
Fibrinolytic / Thrombolytic Agents (e.g., Tissue Plasminogen Activators) Risk of pharmacodynamic antagonism, which may decrease the efficacy of both agents.
Anticoagulants Simultaneous treatment requires strict medical supervision by an experienced physician.

Population-Specific Clearance Consideration

Renal Impairment affects the clearance of Tranexamic Acid. Because the active ingredient is primarily excreted by the kidneys, impaired renal function poses a risk of drug accumulation and subsequent dose-dependent toxicity, requiring clinical consideration related to exposure.

Mechanism of Action

How Clotawin-T Works

Clotawin-T employs a dual-mechanism approach, targeting both the preservation of formed blood clots and the integrity of small vessels, thereby modulating the processes that regulate hemostasis.


Inhibiting Clot Breakdown (Antifibrinolytic Action)

This core mechanism is driven by Tranexamic Acid, which acts as a competitive inhibitor of the enzyme precursor, plasminogen. By binding to the Lysine-Binding Sites on plasminogen, Tranexamic Acid prevents this molecule from attaching to the fibrin clot and being activated into the clot-dissolving enzyme plasmin. This action results in the suppression of the fibrinolytic pathway, which preserves the integrity of the existing fibrin matrix by reducing the rate of fibrin degradation.


Reinforcing Capillary Walls (Angioprotective Action)

The second, complementary mechanism involves Ethamsylate, which targets the microvasculature and primary hemostasis. This component modulates hemostasis by increasing the resistance and decreasing the permeability of capillary endothelial walls. This action, combined with an enhanced local adhesion of platelets, contributes to the immediate reinforcement of the microvasculature, resulting in a modulated efflux of fluid from the microvasculature.

Dosage and Administration Information

Official Administration Guidelines

Clotawin-T, a combination medicine containing tranexamic acid and ethamsylate, is used according to established clinical protocols for its active components.

Administration Scope Details
Route of Administration Primarily Oral (Tablet). Intravenous [IV] administration is available for the tranexamic acid component in specific clinical settings.
Dosing Schedule For the tablet (e.g., 250mg/250mg strength), the standard adult regimen is typically one tablet two to three times a day (every 8 to 12 hours). Total dosage must not exceed the specified maximum daily dose.
Timing in relation to Meals The tablet may be taken with or without food. To maintain consistency, taking the dose at a fixed time each day is recommended.
Preparation Requirements The tablet must be swallowed whole with water. Do not chew, crush, or break the tablet, as maintaining the integrity of the tablet is necessary for proper release. IV injection, when used, must be given slowly and not via the intramuscular route.
Population-Specific Rules Dose adjustment is required for patients with renal impairment due to the accumulation risk of tranexamic acid. The combination product is generally not recommended for use in children under 18 years.
Course Duration / Cyclic Use For use during menstruation, treatment is typically restricted to a maximum of 5 days during the menstrual period. Treatment should not begin until menstrual bleeding has started.
Missed-Dose Rules If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose must be skipped. Do not double the dose to make up for a missed one.

These administration guidelines define the standard procedure for using the medicine, including the route, frequency, and duration of the course.

Recent Clinical Evidence

Summary of Core Research

The drug Clotawin-T is a fixed-dose combination often containing tranexamic acid and ethamsylate. Its development focused on addressing excessive bleeding in various clinical settings. Research has concentrated on the components' actions: tranexamic acid acts as an antifibrinolytic to stabilize blood clots, while ethamsylate is studied for its role in enhancing platelet adhesiveness and strengthening capillary resistance.


Key Clinical Trial Findings

Heavy Menstrual Bleeding (Menorrhagia)

Multiple randomized controlled trials (RCTs) have evaluated the use of tranexamic acid, one of the components, for heavy menstrual bleeding. Studies consistently report a reduction in menstrual blood loss compared to placebo. A meta-analysis examining the use of the combination therapy reported a favorable response in reducing blood loss and improving quality of life indicators for women experiencing this condition.

Surgical and Trauma Settings

Evidence from large, multi-center trials suggests that one of the drug's components, tranexamic acid, may be associated with reduced blood loss and transfusion requirements when administered shortly after significant trauma or during certain surgeries. Research continues to define the optimal timing and dose in these critical settings.


Safety Profile Noted in Studies

Clinical data indicates the drug is generally associated with gastrointestinal effects, such as nausea and diarrhea, and common side effects like headache and musculoskeletal pain. Trials specifically track the risk of thromboembolic events (blood clots), which remains a key area of study; available data in many major trials do not show a clear increase in this risk compared to placebo, though the potential remains a consideration for certain high-risk patients. Research on use during pregnancy and breastfeeding is limited, and current findings are not definitive.

Key Studies & References

  1. Tranexamic Acid Treatment for Heavy Menstrual Bleeding: A Randomized, Double-Blind, Placebo-Controlled Trial (LYSTEDA trial)

Frequently Asked Questions (FAQ)

Common questions about Clotawin-T (FAQ)

Q: How quickly does Clotawin-T start working after taking it?

Official information indicates that the medicine may take several hours, or up to 24 hours in some cases, for the full anti-bleeding effect to be established. This time frame is related to how long it takes for the active ingredients to be absorbed into the body.

Q: How long does the effect of one dose of Clotawin-T last?

The medicine is typically prescribed to be taken two or three times per day, often every 8 to 12 hours. The prescribed frequency is intended to maintain a consistent level of the active substance in the body to support the management of bleeding conditions.

Q: What is the difference between Clotawin-T and other medicines for similar conditions?

Clotawin-T is defined by its composition as a combination medicine. It contains two active ingredients, Tranexamic Acid and Ethamsylate, which provide a dual-action composition to control bleeding. This dual approach differentiates it from single-ingredient formulations used for similar purposes.

Q: Can people with liver problems use Clotawin-T?

Official regulatory documents specifically list restrictions for patients with severe renal (kidney) impairment due to the risk of drug accumulation. Liver impairment is not listed as a contraindication in the same way; however, all underlying health conditions require clinical consideration.

Q: What is the purpose of the 'T' in the drug name Clotawin-T?

The 'T' in Clotawin-T is understood to be a simple naming convention. It indicates the presence of Tranexamic Acid, which is the antifibrinolytic component and one of the two main active ingredients in this combination medicine.

Q: What happens if someone accidentally takes too much Clotawin-T?

Regulatory documents list known symptoms associated with an overdose, which may include severe gastrointestinal effects (nausea, vomiting, diarrhea), dizziness, and changes in vision. Information regarding actions to take in the event of an overdose is available from emergency medical services.

Q: Does Clotawin-T interact with alcohol?

Official labeling indicates that concurrent use with alcohol may lead to excessive drowsiness or central nervous system depression. This is noted in the official warnings section.

Q: Can Clotawin-T be divided or crushed?

Regulatory instructions state that the tablet must be swallowed whole with water and not chewed, crushed, or broken. This administration condition is required to ensure the medicine is released into the body as intended by the manufacturer.

Q: What happens when Clotawin-T is stopped suddenly?

Official information indicates that stopping the medicine prematurely may lead to the recurrence of the underlying bleeding condition for which it was prescribed. The medicine is intended to manage the bleeding episode over the prescribed course of treatment.

Q: Are there any common side effects of Clotawin-T that usually go away?

Commonly reported adverse reactions include mild gastrointestinal effects, such as nausea and diarrhea, as well as headache. Official safety information indicates that these effects are sometimes temporary and may lessen or resolve with continued use.

Q: Can Clotawin-T affect my ability to drive or operate machinery?

The medicine is generally not known to impair the ability to drive or use machinery. However, the occurrence of side effects such as dizziness or visual disturbances may affect concentration, and the presence of those effects may necessitate avoiding such activities.

Q: Is it necessary to have blood tests done while taking Clotawin-T?

Official information indicates that patients with known renal (kidney) impairment may require monitoring or specific tests to assess kidney function. This may be necessary for clinical consideration due to the risk of drug accumulation in those with compromised renal function.

Q: Does Clotawin-T cause weight changes?

Weight changes are not listed in the official regulatory documentation as a common or serious side effect associated with the use of this medicine. Side effects are based on reports from clinical trials and post-market surveillance.

Q: Can Clotawin-T affect mood or cause anxiety?

Changes in mood or anxiety have been described in reports, often in connection with overdose or as a rare reaction. Official safety information does list convulsions (seizures) as a serious, rare adverse event, which is a central nervous system effect.

Q: What type of doctor usually prescribes Clotawin-T?

The medicine is primarily intended for conditions like heavy menstrual bleeding and other systemic bleeding control, according to official information. Therefore, it is commonly prescribed by specialists such as gynecologists or hematologists, and may also be prescribed by other specialists depending on the underlying cause of bleeding.

Q: Can Clotawin-T be taken on an empty stomach?

Yes, the official administration guidelines explicitly state that the tablet may be taken either with food or on an empty stomach. Official information suggests maintaining consistency by taking the dose at a fixed time each day.

Q: What information is available about long-term use of Clotawin-T?

The medicine is typically prescribed for short-term or cyclic use, such as for a maximum of five days during menstruation. Official research and labeling primarily focus on the safety and efficacy of use within these restricted time frames rather than indefinite long-term administration.

How should Clotawin-T be stored and disposed of?

How to Store and Dispose of Clotawin-T

Clotawin-T must be stored strictly according to the conditions specified on the regulatory label to maintain its stability. The product must be stored below 30 C and should be protected from light and moisture.


Packaging and Safety

Requirement Status
Temperature Limit Store below 30 C
Container Rule Keep in the original container and tightly closed
Child Safety Keep out of the sight and reach of children

Disposal of Unused Medicine

Any unused or expired Clotawin-T must be handled as pharmaceutical waste. Official instructions state not to dispose of the product via wastewater or household trash. The medicine must be discarded according to local regulatory requirements or returned to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clotawin-T  found in:

A-Z Index: